Pulmonology Advisor

Long-Term Nintedanib May Stabilize Disease Progression in SARD-ILD-PPF

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.
ascopubs.org

Comparison of incidence and pattern of interstitial lung disease (ILD) during erlotinib and gefitinib treatment in Japanese pts with NSCLC

Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression ...
Healio

Early recognition of SSc-ILD patients who 'progress faster' crucial to avoid complications

Please provide your email address to receive an email when new articles are posted on . Early intervention is critical for patients who are likely to progress to serious complications from systemic ...
Medindia

Detection Tool for Interstitial Lung Disease (ILD) Developed by IIT Kharagpur Researchers

A decision support system that helps diagnose malignant lung tissues and other interstitial lung diseases (ILD) was developed by a team of researchers from IIT Kharagpur. "Biopsy especially in the ...
Medscape

New Model Predicts Risk for Progression of RA-ILD

The risk for progression of rheumatoid arthritis–associated interstitial lung disease (RA-ILD) was higher in patients with a usual interstitial pneumonia (UIP) pattern, an ILD extent of > 10%, and a ...
Medscape

TNF Inhibitors May Be OK for Treating RA-Associated Interstitial Lung Disease

SAN DIEGO — Patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) who start a tumor necrosis factor inhibitor (TNFi) appear to have rates of survival and respiratory-related ...